ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

The Rate of Disability in Pediatric Patients with SLE

Richard Quinn  |  July 16, 2018

Recent research found 41% of pediatric patients with SLE are affected by at least mild disability, with higher pain scores correlating with increased disability. Mary Beth Son, MD, says determining how these children feel and what affects them daily is vital to “identifying targets we can hit as clinicians to improve their quality of life.”

Filed under:ConditionsSystemic Lupus Erythematosus

Results from Belimumab Safety Study

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2018

In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…

Filed under:Drug Updates Tagged with:belimumaborgan damageorgan failureSLEsystemic lupus erythematosus (SLE)

Neutrophils & B Cells Create Unique Antibodies in Lupus Patients

Lara C. Pullen, PhD  |  July 11, 2018

NETs or LL37-DNA complexes may serve as future targets for SLE therapy. In a recent study, researchers identified a link between neutrophils and NETs, and the activation of self-reactive B cells. Their study describes a neutrophil-B cell interaction unique to lupus…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:B cellsneutrophilssystemic lupus erythematosus (SLE)

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2018

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…

Filed under:AnalgesicsDrug Updates Tagged with:ConsensiDuobriiFDA approvalhypertensionosteoarthritis (OA)PainPain ManagementU.S. Food and Drug Administration (FDA)

Anticonvulsants Unhelpful for Low Back Pain

Marilynn Larkin  |  July 7, 2018

NEW YORK (Reuters Health)—Solid evidence suggests that anticonvulsants provide no benefit for low back or lumbar radicular pain and a high risk of harm, researchers say. “We started the study because these drugs were increasingly being used for low back pain and radiating leg pain, without the support of strong evidence of effectiveness,” principal investigator…

Filed under:Conditions Tagged with:anticonvulsive druglow back painPainPain Management

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Michele B. Kaufman, PharmD, BCGP  |  July 2, 2018

In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…

Filed under:AnalgesicsDrug Updates Tagged with:FDAFDA approvalmeloxicamnonsteroidal antiinflammatory drug (NSAID)Painpost-surgerytramadolU.S. Food and Drug Administration (FDA)

FDA Approves Baricitinib for RA Patients

Michele B. Kaufman, PharmD, BCGP  |  June 25, 2018

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…

Filed under:Drug Updates Tagged with:baricitinibFDA approvalRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)

Bringing Policy & Practice Together: A Conversation with GAC Member Ethan Craig, MD, MHS

Carina Stanton  |  June 21, 2018

In his clinic as a third-year fellow at Johns Hopkins Hospital in Baltimore, Ethan Craig, MD, MHS, says it’s not always easy to hear about patients struggling with step therapy or other barriers to treatment­. However, as a member of the ACR’s Government Affairs Committee (GAC), he says his work to understand and improve policy…

Filed under:Profiles Tagged with:ACR Government Affairs CommitteeEthan CraigJohns Hopkins Hospital

ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program

Mary Beth Nierengarten  |  June 21, 2018

On Sept. 23–25, the ACR will once again hold its annual Advocates for Arthritis fly-in event in Washington, D.C. Held in conjunction with the ACR’s Advocacy 101 course, the fly-in is a great way for members and their patients to learn about issues important to the practice of rheumatology and have the opportunity to actively…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Advocacy 101Advocates for Arthritisfly-in

ACR Responds to Drug Pricing Proposals

Mary Beth Nierengarten  |  June 21, 2018

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:ACR principlesAmerican Patients First Drug Pricing Blueprintdrug policy changesTrump administration’s drug pricing proposals

  • « Previous Page
  • 1
  • …
  • 156
  • 157
  • 158
  • 159
  • 160
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences